April 21, 2016
AbbVie, a global biopharmaceutical company, and argenx, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for treating severe autoimmune diseases and cancer will work together to develop and commercialize ARGX-115. This is argenx’ preclinical-stage human antibody program that targets the novel immuno-oncology protein called GARP, which is believed to contribute to immuno-suppressive effects of T-cells.
Tim van Hauwermeiren, Chief Executive Officer of argenx, said: “ARGX-115 has been developed in collaboration with an outstanding team of academics at the de Duve Institute / Université Catholique de Louvain through our Innovative Access Program, which gives argenx rights to novel, exciting targets in our areas of therapeutic focus. We believe ARGX-115 has the potential to advance immuno-oncology by selectively targeting tumor immune escape pathways. We are proud to develop and commercialize ARGX-115 through collaboration with AbbVie, a global leader in oncology. In addition to the attractive financial elements of this transaction, our shared interest in the commercial potential of ARGX-115, including the right to co-promote the drug in Europe, makes this a highly strategic collaboration for argenx.”
“The ability to modulate the body’s own immune system to fight cancer is one of the most promising scientific advancements over the past decade. We believe that the ARGX-115 program is a unique opportunity to explore the potential to block certain immune-suppressive pathways that allow cancers to grow,” said Anil Singhal, Vice President, Early Oncology Development, AbbVie.AbbVie and argenx sign $685M deal for preclinical immuno-oncology last edit: 2016-05-03T18:30:07+00:00 da